Stem cells for heart failure
Friday, 06 June, 2008
Mesoblast (ASX: MSB) will soon launch phase II trials into congestive heart failure, the company said.
The trials will be conducted by its US-based sister company Angioblast Systems.
The US FDA recently granted the companies permission to perform clinical trials using its adult stem cell-based treatment.
45 clients suffering from congestive heart failure will be given allogeneic stem cells, while 15 will be given a placebo.
The stem cells will be injected directly into the patients' hearts through a cardiac catheter.
In pilot trials conducted in Australia, a similar injection method using the patients' own cells was shown to improve heart muscle function and reduce the risk of heart failure. Mesoblast said using healthy stem cells will improve the results even further.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
